Literature DB >> 24628233

Glycosylated antitumor ether lipids: activity and mechanism of action.

Gilbert Arthur, Robert Bittman1.   

Abstract

Glycosylated antitumor ether lipids (GAELs) are distinguished from the alkyllysophospholipids or alkylphosphocholines classes of antitumor ether lipids (AEL) by the presence of a sugar moiety. Non-phosphorus GAELs, the subject of this review, have a sugar moiety in place of the phosphobase found in alkyllysophospholipids. Analogues of non-phosphorus GAELs with glucose, maltose, arabinose, or disaccharide moieties have been synthesized. Non-phosphorus GAELs with monosaccharides have cytotoxic and antiproliferative effects against cancer cells derived from a wide range of tissues, including drug resistant cell lines. The most active compound of this group to date is 1-O-hexadecyl-2-O-methyl-3-O-(2'-amino-2'-deoxy-β-D-glucopyranosyl)-sn-glycerol (11), which displays in vitro activity similar to or greater than that of ET-18-OCH3, the AEL "gold" standard. While the detailed molecular mechanism of action of non-phosphorus GAELs is not known, the data indicate that non-phosphorus GAELs are taken up by endocytosis and incorporated into early endosomes. The presence of non-phosphorus GAELs perturbs the maturation of the endocytic vesicles, resulting in the formation of large acidic vacuoles. Cell death appears to be the result of the release of cathepsins from the vacuoles into the cytosol and subsequent activation of a death pathway that is independent of the mitochondria and independent of apoptosis. The ability of these GAELs to kill cells via an apoptosis-independent mechanism makes them prime candidates for development of effective compounds against chemo-resistant tumors and cancer stem cells. The disaccharide-linked GAELs do not have cytotoxic activity but rather inhibit cancer cell motility due to the ability of the compounds to block specific calcium-activated potassium channels in cells. The antitumor activities displayed by these experimental compounds augurs well for their eventual development into clinically useful agents for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24628233     DOI: 10.2174/1871520614666140309231144

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  3 in total

1.  Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.

Authors:  Amani I Moraya; Jennifer L Ali; Pranati Samadder; Lisa Liang; Ludivine Coudière Morrison; Tamra E Werbowetski-Ogilvie; Makanjuola Ogunsina; Frank Schweizer; Gilbert Arthur; Mark W Nachtigal
Journal:  J Exp Clin Cancer Res       Date:  2017-05-12

2.  Synthesis of Alkyl-Glycerolipids Standards for Gas Chromatography Analysis: Application for Chimera and Shark Liver Oils.

Authors:  Michelle Pinault; Cyrille Guimaraes; Hélène Couthon; Jérôme Thibonnet; Delphine Fontaine; Aurélie Chantôme; Stephan Chevalier; Pierre Besson; Paul-Alain Jaffrès; Christophe Vandier
Journal:  Mar Drugs       Date:  2018-03-23       Impact factor: 5.118

3.  Syntheses of L-Rhamnose-Linked Amino Glycerolipids and Their Cytotoxic Activities against Human Cancer Cells.

Authors:  Makanjuola Ogunsina; Pranati Samadder; Temilolu Idowu; Mark Nachtigal; Frank Schweizer; Gilbert Arthur
Journal:  Molecules       Date:  2020-01-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.